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Editorial Comment
Optimal Therapy for Cardiogenic
Shock: The Emerging Role of
Coronary Angioplasty*
LLOYD w. KLEIN, MD, FACC
Chicago, Illinois
Does an aggressive approach to the management of cardio-
genic shock due to acute myocardial infarction ameliorate its
substantial in-hospital mortality rate (1 ,2)? Although balloon
angioplasty is an excellent method for opening acutely
occluded vessels, specific circumstances in which its use
improves prognosis have not been established. Furthermore,
the efficacy of the new hemodynamic support techniques and
the benefit of thrombolytic therapy in cardiogenic shock as
complements to additional intervention are uncertain. It is
also increasingly apparent that cost is an issue; it is no longer
acceptable to utilize an expensive procedure if it cannot be
shown to affect ultimate outcome in clinical trials. Within
this context, two studies (3,4) published in this issue of the
Journal promise to influence subsequent discourse and fu-
ture investigation. In conjunction with previous findings,
these new studies confirm that angioplasty is beneficial in
selected patients with cardiogenic shock. In addition, they
preliminarily identify certain patient subgroups that are most
likely to benefit from immediate intervention, explore the
role of hemodynamic support devices and highlight the many
subtle features of this patient group that complicate the
design and performance of more definitive trials. Conse-
quently, the optimal therapy for different categories of
patients with cardiogenic shock needs to be reevaluated in
view of these new data.
Traditional approach. To achieve survival of patients
with cardiogenic shock, an expeditious diagnostic evaluation
must be performed simultaneously with clinical stabilization
(5), which typically necessitates the use of vasopressors,
inotropic agents and, often, an intraaortic balloon pump.
These are primarily temporizing measures, because they
have minimal effect on in-hospital mortality. However, when
systemic perfusion is restored and clinical status improves,
invasive procedures and bypass surgery can then be per-
formed with an improved outcome (5-7).
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Immediate revascularization. Since the original demon-
stration (7) that urgent surgical revascularization results in a
dramatic improvement in the survival rate of patients with
cardiogenic shock, subsequent studies have sought to repro-
duce these results using nonsurgical reperfusion techniques.
Cardiologists have aggressively pursued urgent recanaliza-
tion in recognition of the theoretic advantages of patency of
the infarct-related artery, and supported by rapid technical
advances in the methodology of restoring coronary flow
under dire circumstances. Such efforts continue even as
clinical experience reveals that urgent surgical revascular-
ization is pragmatically difficult to arrange (3) and its results
are often less than impressive in patients whose condition is
highly unstable (4).
Thrombolysis, which is widely considered to decrease the
in-hospital and I-year mortality rate of patients with acute
myocardial infarction by 2% to 6% (8), has had disappointing
results in the subgroup of patients with cardiogenic shock.
Neither intracoronary streptokinase (9), intravenous strep-
tokinase (10) nor recombinant tissue-type plasminogen acti-
vator (rt-PA) (11) appears to reduce the mortality rate of
these patients. Moreover, the risk of severe hemorrhage
after the administration of thrombolytic agents in patients
who routinely undergo hemodynamic monitoring and sup-
port, invasive and interventional procedures and perhaps
bypass surgery is undoubtedly increased, markedly limiting
enthusiasm for this approach as a stand-alone strategy.
Direct angioplasty. Although the value of direct angio-
plasty for acute myocardial infarction is currently being
reappraised (12,13), its utility in the subgroup of patients
with cardiogenic shock has always been the subject of active
investigation. This continued interest is a strong indication
of the lack of effectiveness of other measures: shock is the
clinical variable most predictive of mortality (12,14,15) and
early reocclusion (16) in patients with infarction treated by
direct angioplasty.
Several studies (17-21) have shown that if immediate
angioplasty is successful, an in-hospital survival rate of 60%
to 85% can be expected, as compared with a rate of 0% to
25% if it is unsuccessful. These results demonstrate that
emergency angioplasty performed in highly selected patients
can have a good outcome; however, a cautious interpreta-
tion of these data is warranted (22) for several reasons. First,
the qualifying criteria for study entry and their application
varied; in at least one study (17), many patients appeared to
fail to meet the commonly accepted definition of cardiogenic
shock based on hemodynamic variables (5). This problem is
compounded by the rapid hemodynamic stabilization re-
quired to maintain survival, which necessarily alters the
determination of qualifying characteristics. Also, some pa-
tients included in these series underwent rescue angioplasty
after thrombolysis had failed rather than direct angioplasty;
rescue angioplasty is associated with lower patency rates
than those that occur with direct angioplasty (22). Addition-
ally, none of these studies included a concurrently selected
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control group; retrospective identification (17) failed to
alleviate concerns about patient selection bias. Indeed, these
studies were not designed to choose a consecutive series of
patients, inevitably raising questions regarding those varia-
bles used to decide which qualified patients were taken to the
catheterization laboratory and which, and how many, were
not. These unidentified exclusion criteria may have substan-
tially affected the study conclusions.
Combined thrombolysis and angioplasty. Another impor-
tant consideration is that on presentation, some patients are
mildly hypotensive but not in frank shock; they receive
thrombolytic therapy and if their condition deteriorates or
fails to improve they are taken to the catheterization labo-
ratory. Some insight into combining methods of reperfusion
in this setting can be drawn from a small series of patients
with cardiogenic shock who were included in a much larger
group of patients with acute infarction and treated with
angioplasty after either intravenous streptokinase (23) or
rt-PA (24). In these studies, shock was again the variable
most predictive of outcome, with a 42% in-hospital mortality
rate. This rate is at the high end of the range reported with
successful direct angioplasty, perhaps because patients were
classified as being in shock after the thrombolytic agent was
given and apparently failed; a substantial number of patients
became hypotensive only during catheterization. In general,
a lower rate of reocclusion has been noted in patients with
acute infarction who are treated with combined therapy
(24,25), but no inference can be made with respect to
patients in shock. Thus, a categoric assessment of thrombol-
ysis followed by angioplasty as a primary strategy (' 'imme-
diate" angioplasty [22]) in patients presenting with cardio-
genic shock requires further examination.
The current studies. The results of Hibbard et al. (3) from
the Mayo Clinic demonstrate that successful acute angio-
plasty in selected patients has beneficial short- and long-term
effects. Of 45 patients, 28 (62%) underwent successful acute
angioplasty, with a 71% in-hospital survival rate as com-
pared with a 29% survival rate in patients in whom angio-
plasty failed. The mean follow-up period of
2.3 years is especially significant, extending previous obser-
vations (21,24) in documenting an excellent prognosis and a
relatively high quality of life after hospital discharge. Be-
cause a diminished ejection fraction is often observed (21)
during shock, serial studies would be useful to assess the
mechanism of improved prognosis. All five deaths during
follow-up were in patients with successful acute angioplasty,
an experience similar to that of Lee et al. (21); these findings
suggest that some patients should undergo angioplasty for
immediate stabilization with bypass surgery performed soon
thereafter. Additionally, Hibbard et al. (3) present new data
indicating that patient age and a history of prior infarction
are predictive of outcome but that certain complex stenosis
morphologies and the number of diseased vessels are not.
About 30% of the patients received thrombolytic therapy for
various indications, but 60% had angioplasty only after this
therapy failed. All patients underwent intervention within
24 h of the onset of shock, and reperfusion was achieved in
half of the patients by <6 h.
The study by Gacioch et al. (4) contains several interest-
ing features. During a 5-year period, 48 patients with car-
diogenic shock underwent angioplasty at the University of
Michigan. This patient group represented 71%of all patients
with cardiogenic shock; 9patients did not have an angiogram
performed and 11 additional patients underwent angiography
but did not undergo angioplasty. A successful angioplasty
result was achieved in 73% with a 61% in-hospital survival
rate versus only a 7% survival rate in the patients with failed
angioplasty. Of the total 68-patient group, 46% had throm-
bolysis with various agents, but insufficient information is
presented to analyze its effect on outcome. The timing of
catheterization was variable, but most studies were per-
formed within 12 h of the onset of the shock syndrome.
Neither emergency surgery nor newer support devices
seemed to salvage a single patient (although the hemopump
was used in two patients who survived to hospital dis-
charge), perhaps because their use was restricted to patients
in the most unstable condition. Only patient age predicted
survival.
Several important discrepancies in the results of these
two studies are as illustrative as their common conclusions.
Hibbard et al. (3) pointedly conclude that the number of
diseased vessels is unimportant in determining outcome;
Gacioch et al. (4) emphasize that patients with single-vessel
disease do much better. Of the patients with failed angio-
plasty, 29% at the Mayo Clinic (3) survived to hospital
discharge versus only 7% of the group in Michigan (4), a
difference probably related to patient population and case
selection. Finally, the value of hemodynamic support is not
considered by Hibbard et al. (3), whereas Gacioch et al. (4)
utilized support devices in 12 of their 68 patients.
Conclusions and questions. Thus, on the basis of pub-
lished studies and clinical experience, it is concluded that
urgent angioplasty improves short- and long-term outcome
in many patients with cardiogenic shock. The precise role of
angioplasty is emerging, but it will clearly be more effective
in some patient subgroups than in others. Urgent interven-
tion should be strongly considered after initial stabilization
in patients aged <65 years who present with shock during
their first infarction. When the clinical characteristics are
less favorable, the appropriate course is less certain.
The factors most likely to be predictive of angioplasty
success and ultimate outcome are 1) degree of diminished
left ventricular function before the current infarction, that is,
a history of one or more prior infarctions; 2) severity and
diffuseness of coronary atherosclerosis, both in the infarct-
related artery and in additional arteries, that is, the number
of diseased vessels; 3) patient age; 4) time from the onset of
shock to the reestablishment of coronary flow; 5) demon-
stration of a large thrombus or ulcerated plaque on angiog-
raphy; and 6) failure of thrombolytic therapy. Further stud-
ies will be needed to determine the best approach when
adverse clinical factors are present. One crucial question is
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whether angiography and angioplasty should be reserved for
those subgroups of patients most likely to benefit.
There are other lingering questions as well. When the
angiographic findings suggest that angioplasty will be tech-
nically difficult or likely to lead to complications, should
such patients undergo immediate bypass surgery, be given
an intracoronary thrombolytic agent (which has a low like-
lihood of success [21,26]) or receive some other therapy?
Does intravenous thrombolysis have an adjunctive role to
angioplasty? In which patients should immediate angioplasty
be employed primarily as a bridge to surgery rather than as
definitive therapy? Would the new hemodynamic support
devices improve outcome if placed earlier? Would modifica-
tion of existing devices to allow more prolonged hemody-
namic support while the patient awaits heart transplantation
be worthwhile in patients in whom immediate recanalization
is ineffective? Will atherectomy or laser or other devices
improve these results? The answers to such questions will
require exceptionally thoughtful trials incorporating serial
measurements of left ventricular function, a control group
and a separate analysis of patients given thrombolytic ther-
apy, specifically with regard to angioplasty strategy. Never-
theless, with publication of the studies by Hibbard (3) and
Gacioch (4) and their coworkers, the questions have changed
and a new phase of study begins.
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